Research programme: cancer therapies - LipoNova
Alternative Names: LN020; LN030; LN040Latest Information Update: 07 Oct 2009
At a glance
- Originator Liponova AG
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Leukaemia; Solid tumours
Most Recent Events
- 07 Oct 2009 Discontinued - Preclinical for Leukaemia in Germany (unspecified route)
- 07 Oct 2009 Discontinued - Preclinical for Solid tumours in Germany (unspecified route)
- 20 Apr 2007 Preclinical trials in Leukaemia in Germany (unspecified route)